ABEONA THERAPEUTICS INC. - 8-K Filing
Abeona Therapeutics participated in a pre-Investigational New Drug (Pre-IND) meeting with the FDA on June 3, 2026 regarding ABO-701, an engineered T-cell therapy targeting prostate cancer. The company expects to submit an IND application for ABO-701 by 2027 but noted that this timeline is subject to change based on regulatory feedback and other factors. (Items: 8.01 Other Events On June 3, 2026, Abeona Therapeutics Inc)
Tickers: $ABEO